Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.41)
# 471
Out of 4,479 analysts
85
Total ratings
41.24%
Success rate
34.01%
Average return
Main Sectors:
Top Industries:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALT Altimmune | Reiterates: Buy | $20 | $7.20 | +177.78% | 7 | Jun 25, 2024 | |
| CYTK Cytokinetics | Maintains: Buy | $122 → $92 | $54.70 | +68.19% | 2 | Jun 4, 2024 | |
| GRTS Gritstone bio | Reiterates: Buy | $6 → $3 | $0.58 | +417.24% | 3 | May 24, 2024 | |
| NVAX Novavax | Maintains: Buy | $11 → $29 | $12.73 | +127.81% | 11 | May 23, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $270 → $200 | $279.31 | -28.39% | 7 | May 10, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $5 | $1.67 | +199.40% | 1 | Mar 28, 2024 | |
| TGTX TG Therapeutics | Maintains: Buy | $24 → $29 | $18.15 | +59.78% | 10 | Feb 5, 2024 | |
| VXRT Vaxart | Upgrades: Buy | $2 | $0.69 | +190.44% | 4 | Jan 31, 2024 | |
| CKPT Checkpoint Therapeutics | Maintains: Buy | $8 → $4 | $2.05 | +95.12% | 2 | Dec 20, 2023 | |
| SCLX Scilex Holding Company | Initiates: Buy | $4 | $1.88 | +112.77% | 1 | Oct 13, 2023 | |
| DNLI Denali Therapeutics | Initiates: Buy | $38 | $22.01 | +72.65% | 1 | Sep 6, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $55 | $26.05 | +111.13% | 5 | Jul 20, 2023 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $6 | $2.89 | +107.61% | 1 | Apr 12, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $7 → $3 | $0.59 | +408.99% | 3 | Apr 10, 2023 | |
| AGEN Agenus | Reiterates: Buy | $160 | $16.69 | +858.66% | 1 | Mar 29, 2023 | |
| GANX Gain Therapeutics | Downgrades: Neutral | $11 → $5 | $1.12 | +346.43% | 3 | Aug 19, 2022 | |
| SAVA Cassava Sciences | Maintains: Buy | $58 → $44 | $12.14 | +262.44% | 3 | Aug 11, 2022 | |
| FBIO Fortress Biotech | Maintains: Buy | $120 → $90 | $1.69 | +5,225.44% | 3 | Jul 14, 2022 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $0.95 | +319.24% | 1 | Jun 14, 2022 | |
| INMB INmune Bio | Downgrades: Neutral | $14 → $7 | $8.42 | -16.86% | 2 | May 24, 2022 | |
| TFFP TFF Pharmaceuticals | Maintains: Buy | $600 → $450 | $1.78 | +25,180.90% | 1 | Mar 29, 2022 | |
| SEEL Seelos Therapeutics | Maintains: Buy | $1,440 → $960 | $0.62 | +154,988.85% | 2 | Mar 14, 2022 | |
| MBIO Mustang Bio | Maintains: Buy | $195 → $90 | $0.48 | +18,479.69% | 1 | Jan 24, 2022 | |
| BIVI BioVie | Maintains: Buy | n/a | $0.42 | - | 1 | Nov 30, 2021 | |
| ELOX Eloxx Pharmaceuticals | Initiates: Buy | n/a | $0.70 | - | 1 | May 27, 2021 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Neutral | n/a | $23.66 | - | 2 | Jan 15, 2021 | |
| ACST Acasti Pharma | Upgrades: Buy | n/a | $2.92 | - | 1 | Jul 6, 2020 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Neutral | n/a | $0.29 | - | 2 | May 22, 2020 | |
| GALT Galectin Therapeutics | Maintains: Buy | n/a | $2.35 | - | 1 | Apr 3, 2020 | |
| MNOV MediciNova | Maintains: Buy | n/a | $1.44 | - | 1 | Mar 13, 2020 | |
| GNFT Genfit | Maintains: Buy | n/a | $4.00 | - | 1 | Mar 13, 2020 |
Altimmune
Jun 25, 2024
Reiterates: Buy
Price Target: $20
Current: $7.20
Upside: +177.78%
Cytokinetics
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $54.70
Upside: +68.19%
Gritstone bio
May 24, 2024
Reiterates: Buy
Price Target: $6 → $3
Current: $0.58
Upside: +417.24%
Novavax
May 23, 2024
Maintains: Buy
Price Target: $11 → $29
Current: $12.73
Upside: +127.81%
Madrigal Pharmaceuticals
May 10, 2024
Maintains: Neutral
Price Target: $270 → $200
Current: $279.31
Upside: -28.39%
Cognition Therapeutics
Mar 28, 2024
Reiterates: Buy
Price Target: $5
Current: $1.67
Upside: +199.40%
TG Therapeutics
Feb 5, 2024
Maintains: Buy
Price Target: $24 → $29
Current: $18.15
Upside: +59.78%
Vaxart
Jan 31, 2024
Upgrades: Buy
Price Target: $2
Current: $0.69
Upside: +190.44%
Checkpoint Therapeutics
Dec 20, 2023
Maintains: Buy
Price Target: $8 → $4
Current: $2.05
Upside: +95.12%
Scilex Holding Company
Oct 13, 2023
Initiates: Buy
Price Target: $4
Current: $1.88
Upside: +112.77%
Denali Therapeutics
Sep 6, 2023
Initiates: Buy
Price Target: $38
Current: $22.01
Upside: +72.65%
Arrowhead Pharmaceuticals
Jul 20, 2023
Reiterates: Buy
Price Target: $55
Current: $26.05
Upside: +111.13%
Trevi Therapeutics
Apr 12, 2023
Initiates: Buy
Price Target: $6
Current: $2.89
Upside: +107.61%
X4 Pharmaceuticals
Apr 10, 2023
Maintains: Buy
Price Target: $7 → $3
Current: $0.59
Upside: +408.99%
Agenus
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $16.69
Upside: +858.66%
Gain Therapeutics
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.12
Upside: +346.43%
Cassava Sciences
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $12.14
Upside: +262.44%
Fortress Biotech
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.69
Upside: +5,225.44%
Lineage Cell Therapeutics
Jun 14, 2022
Initiates: Buy
Price Target: $4
Current: $0.95
Upside: +319.24%
INmune Bio
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $8.42
Upside: -16.86%
TFF Pharmaceuticals
Mar 29, 2022
Maintains: Buy
Price Target: $600 → $450
Current: $1.78
Upside: +25,180.90%
Seelos Therapeutics
Mar 14, 2022
Maintains: Buy
Price Target: $1,440 → $960
Current: $0.62
Upside: +154,988.85%
Mustang Bio
Jan 24, 2022
Maintains: Buy
Price Target: $195 → $90
Current: $0.48
Upside: +18,479.69%
BioVie
Nov 30, 2021
Maintains: Buy
Price Target: n/a
Current: $0.42
Upside: -
Eloxx Pharmaceuticals
May 27, 2021
Initiates: Buy
Price Target: n/a
Current: $0.70
Upside: -
Arcturus Therapeutics Holdings
Jan 15, 2021
Downgrades: Neutral
Price Target: n/a
Current: $23.66
Upside: -
Acasti Pharma
Jul 6, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.92
Upside: -
Galmed Pharmaceuticals
May 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $0.29
Upside: -
Galectin Therapeutics
Apr 3, 2020
Maintains: Buy
Price Target: n/a
Current: $2.35
Upside: -
MediciNova
Mar 13, 2020
Maintains: Buy
Price Target: n/a
Current: $1.44
Upside: -
Genfit
Mar 13, 2020
Maintains: Buy
Price Target: n/a
Current: $4.00
Upside: -